Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 6/20 | 0.88 |
| ▸ | CTSL | P07711 | 6/20 | 0.88 |
| ▸ | GHSR | Q92847 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GABRP | O00591 | 1/20 | 0.49 |
| ▸ | GABRD | O14764 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472923 | 1.00 | CTSV (0.88) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL2821600 | 0.95 | CTSV (0.97) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL29411985 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL21065454 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL30472916 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL25422114 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL25424145 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL472759 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL30913016 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 | |
| SCHEMBL29367405 | 0.94 | CTSV (1.00) | CTSVCTSLGHSRGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118108771-A | Method for preparing quinolone compound by high-efficiency catalysis of pyridine palladium | 安康学院 | 2024-05-31 | — | — | CN | disclosed |
| US-20240002348-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-01-04 | — | — | US | disclosed |
| EP-4204410-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research, an Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022044033-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860)) (IN) | 2022-03-03 | — | — | WO | disclosed |
| EP-0498723-B1 | Nitrogen containing bicycle compounds, method for their preparation, their use as pharmaceutical and compositions containing them | AVENTIS PHARMA SA (FR) | 2001-09-19 | — | — | EP | disclosed |
| EP-0498721-B1 | N-substituted quinoline derivatives, process for their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (FR) | 1999-12-22 | — | — | EP | disclosed |
| US-6004979-A | ANGIOTENSIN II INHIBITORS; 4-((CARBOXY)ARYLOXY)-QUINOLINE DERIVATIVES | HOECHST MARION ROUSSEL (FR) | 1999-12-21 | — | — | US | disclosed |
| US-5985894-A | USEFUL IN THE TREATMENT OF CARDIOVASCULAR ILLNESSES | HOECHST MARION ROUSSEL (FR) | 1999-11-16 | — | — | US | disclosed |
| US-5817674-A | ANTIOTENSIN II RECEPTOR ANTAGONISTS | ROUSSEL UCLAF (FR) | 1998-10-06 | — | — | US | disclosed |
| EP-0498722-B1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-07-30 | — | — | EP | disclosed |
| US-5478938-A | Antagonists for angiotensin II receptors; hypotensive, cardiotonic agents; cognitive activators | ROUSSEL UCLAF (FR) | 1995-12-26 | — | — | US | disclosed |
| US-5444071-A | Hypotensive agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-08-22 | — | — | US | disclosed |
| EP-0412848-B1 | Quinoline derivatives, process for their preparation and their use as medicaments | ICI PLC (GB) | 1995-01-18 | — | — | EP | disclosed |
| US-5324839-A | Hypotensive agents, gastrointestinal and urogenital disorders | ROUSSEL-UCLAF (FR) | 1994-06-28 | — | — | US | disclosed |
| EP-0498723-A1 | Nitrogen containing bicycle compounds, method for their preparation, their use as pharmaceutical and compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| EP-0498722-A1 | Bicyclic nitrogen compounds, their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| EP-0498721-A1 | N-substituted quinoline derivatives, process for their preparation, intermediates obtained, their use as pharmaceuticals and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1992-08-12 | — | — | EP | disclosed |
| CN-1050187-A | New quinoline compound and preparation method thereof | ICI PLC (GB) | 1991-03-27 | — | — | CN | disclosed |
| EP-0412848-A2 | Quinoline derivatives, process for their preparation and their use as medicaments | ZENECA LIMITED (GB) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002348-A1 | QUINOLONE COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | SQLE, NQO2, CYP1B1 | CTSV 1927/4885CTSL 3665/4885GHSR 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.